HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by COLEMAN, P. G. Articles by MILLS, A. J. Search for Related Content PubMed PubMed Citation Articles by COLEMAN, P. G. Articles by MILLS, A. J.

A THRESHOLD ANALYSIS OF THE COST-EFFECTIVENESS OF ARTEMISININ-BASED COMBINATION THERAPIES IN SUB-SAHARAN AFRICA

Artemisinin-based combination therapies (ACTs) are generally regarded as vital in addressing the growing problem posed by the development of antimalarial resistance across sub-Saharan Africa. However, the costs of the new ACTs are likely to be significantly higher than current therapies. Therefore, it is important to examine formally the cost-effectiveness of the more effective yet more expensive ACTs before advocating a switch in policy. Importantly, any such economic evaluation must consider the temporal dynamics of drug resistance, and not just focus on the static question of whether switching today would be cost-effective at current levels of resistance, particularly since the development of new antimalarials in the future is so uncertain. However, predicting the future changes in drug resistance is a major difficulty in accurately quantifying the relative costs and health outcomes associated with different drug therapies over time. Here, we use a simple decision tree model to estimate the incremental cost-effectiveness of using ACTs, compared with persisting with current therapies, over 5-, 10-, and 15-year periods. We describe the dynamics of drug resistance using a general logistic growth function, in which the starting frequency of resistance and maximum growth may be altered. However, rather than make assumptions about the absolute rate at which resistance to ACTs will progress, we allow the ratio of the growth rate of resistance to ACTs relative to that of current therapies to vary. Defining the growth rate of ACT resistance in this manner allows us to calculate the threshold ratio at which ACTs would no longer appear cost-effective, for any starting conditions of resistance to current therapies and ACTs, and over any time period. The influence of uncertainty in other decision tree parameters on the threshold ratio values is also quantified, using Monte Carlo simulation techniques. This analysis shows that ACTs are more than 95% likely to be cost-effective under most conditions, other than very low levels of initial resistance to sulfadoxine/pyrimethamine and a five-year time frame. These predictions are conservative in that 95% certainty is a stringent decision rule favoring the rejection of new policies. The importance of other variables not included in the analysis for the robustness of the findings are discussed (e.g., consideration of the entire population at risk for malaria, the affordability of ACTs in specific settings, and the growth of resistance modeled according to population genetic parameters).

Received August 21, 2003. Accepted for publication December 8, 2003.

Acknowledgments: We thank Andrew Briggs for facilitating the collaboration between the Health Economics Research Centre (University of Oxford) and the London School of Hygiene and Tropical Medicine and for his input to the modeling.

Financial support: This study was supported by the Institute of Medicine and the World Health Organization.

Authors’ addresses: Paul G. Coleman, Disease Control and Vector Biology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom, Telephone: 44-207-927-2333, Fax: 44-207-580-9075. E-mail: Paul.Coleman{at}lshtm.ac.uk. Chantal Morel, Catherine Goodman, and Anne J. Mills, Health Economics and Financing Program, Department of Public Health and Policy, Health Policy Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom, E-mails: Chantal.Morel{at}lshtm.ac.uk, Catherine.Goodman{at}lshtm.ac.uk, and Anne.Mills{at}lshtm.ac.uk. Samuel Shillcutt, Health Economics Research Centre, University of Oxford, Old Road, Headington, Oxford OX3 7LF, United Kingdom and Department of Economics, School of Social Sciences, City University, Northampton Square, London EC1V 0HB, United Kingdom, E-mail: Samuel.Shillcutt{at}public-health.oxford.ac.uk.

This article has been cited by other articles:

				C. M Morel, J. A Lauer, and D. B Evans Cost effectiveness analysis of strategies to combat malaria in developing countries BMJ, December 3, 2005; 331(7528): 1299. [Abstract] [Full Text] [PDF]

				J Damoiseaux, A van der Ven, R Hermsen, D Telgt, M Roestenberg, J W Cohen Tervaert, and R Sauerwein Experimental infection with Plasmodium falciparum does not result in the induction of anticardiolipin antibodies in healthy volunteers Ann Rheum Dis, December 1, 2005; 64(12): 1804 - 1805. [Full Text] [PDF]

				I. Malhotra, A. Dent, P. Mungai, E. Muchiri, and C. L. King Real-Time Quantitative PCR for Determining the Burden of Plasmodium falciparum Parasites during Pregnancy and Infancy J. Clin. Microbiol., August 1, 2005; 43(8): 3630 - 3635. [Abstract] [Full Text] [PDF]